Ozmosi | Potassium canrenoate Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Potassium canrenoate

Alternative Names: potassium canrenoate
Clinical Status: Inactive
Latest Update: 2026-02-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Aldosterone Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous, Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Czech | France | Poland | Slovenia | Taiwan | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Potassium canrenoate

Countries in Clinic: France, Greece

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2024-513809-31-00

2019PI117

P2

Not yet recruiting

Unknown

2033-06-05

2025-05-02

Treatments

2025-522796-28-00

GEN-100

P2

Withdrawn

Unknown

2027-06-30